Krüppel-like factor 5 (Klf5; IKLF; BTEB2), a zinc-finger transcription factor with proproliferative and transforming properties in vitro, is expressed in proliferating cells of gastrointestinal tract epithelia, including in basal cells of the esophagus. Thus Klf5 is an excellent candidate to regulate esophageal epithelial proliferation in vivo. Nonetheless, the function of Klf5 in esophageal epithelial homeostasis and tumorigenesis in vivo has not previously been determined. Here, we used the ED-L2 promoter of Epstein Barr Virus to express Klf5 throughout esophageal epithelia. ED-L2/Klf5 transgenic mice were born at the appropriate Mendelian ratio, survived to at least one year of age, and showed no evidence of esophageal dysplasia or cancer. Staining for BrdU demonstrated increased proliferation in the basal layer of ED-L2/Klf5 mice, but no proliferation was seen in suprabasal cells, despite ectopic expression of Klf5 in these cells. Notably, expression of the KLF family member Klf4, which binds the same DNA sequences as Klf5 and which inhibits proliferation and promotes differentiation, was not altered in ED-L2/Klf5 transgenic mice. In primary esophageal keratinocytes which overexpressed Klf5, expression of Klf4 still inhibited proliferation and promoted differentiation, providing a possible mechanism for the persistence of keratinocyte differentiation in ED-L2/Klf5 mice. To identify additional targets for Klf5 in esophageal epithelia, we performed functional genomic analyses and identified a total of 15 differentiallyexpressed genes. In sum, while Klf5 positively regulates proliferation in basal cells, it is not sufficient to maintain proliferation in the esophageal epithelium.
Introduction
Diseases of the esophagus are among the most common ailments in the United States and throughout the world. Gastroesophageal reflux disease (GERD) affects up to 44% of the U.S. population at least monthly and approximately 20% have weekly symptoms (16). Some of these patients will develop altered proliferation and differentiation in the esophageal mucosa, with a disease spectrum ranging from symptomatic GERD to erosive esophagitis to Barrett's esophagus to adenocarcinoma of the esophagus (35). Chronic irritation of the mucosa by factors such as alcohol or tobacco use also alters the normal mechanisms of esophageal homeostasis, predisposing to squamous cell cancers of the esophagus (7). Each year, more than 300,000 people worldwide contract esophageal cancer and nearly that many die of the disease (24) . In the United States, esophageal cancer affects more than 14,000 individuals each year and is almost universally fatal (11) . More than 90% of esophageal cancers arise in the epithelium (32) . The common feature of GERD, esophageal cancer, and numerous other esophageal and gastrointestinal diseases is the dysregulation of normal epithelial homeostasis (12) .
A number of proteins have been implicated in the control of epithelial homeostasis and carcinogenesis, including members of the Krüppel-like factor (KLF) family (9) . The KLFs are DNA-binding transcriptional regulators that play a diverse role in proliferation, differentiation, and development. Members of the KLF family bind similar "CACCC" DNA elements. Among the KLFs, two tissue-restricted factors, Klf4 (GKLF) and Klf5 (IKLF; BTEB2), are highly expressed in epithelial cells of the gastrointestinal tract including the esophagus (5, 30, 37) . In the adult, Klf5 is localized to regions of active cell proliferation, including basal cells of the esophagus (5, 21) . During development, Klf5 is first expressed throughout the primitive gut at embryonic day 10.5 (E10.5) and by E17.5 becomes restricted to the base of the intestinal crypts Page 3 of 33 Page 4 (21) . This pattern of expression for Klf5 is opposite that of Klf4, which has been shown to negatively regulate proliferation and promote differentiation, in vitro and in vivo (8, 15, (28) (29) (30) .
Notably, Klf4 opposes the effect of Klf5 on a number of promoters, including Klf4 and LAMA1 (6, 26) .
Substantial data point to a role for Klf5 as a positive regulator of cell proliferation with transforming properties in vitro. In NIH 3T3 cells, for example, transfection of Klf5 promotes proliferation, results in loss of contact inhibition, and mediates transformation by oncogenic HRas via cyclin D1, cyclin B1, and cdc2 (18, 19, 33) . Klf5 is a downstream target of the Wnt pathway (38), activation of which plays a key role in the development of colorectal cancer, and activates LAMA1, which has been linked to malignant progression (26) . In esophageal keratinocytes, Klf5 increases proliferation via EGFR, MEK, and ERK (37) . However, other data suggest that KLF5 may function as a tumor suppressor in esophageal, breast, prostate, and intestinal cancers (2) (3) (4) 36) , leading to some controversy about its role in carcinogenesis. In esophageal cancer cells, for example, Klf5 inhibits proliferation and invasion and promotes apoptosis, including in response to anchorage-independent growth.
To date, little information about the role of Klf5 in epithelial homeostasis and tumorigenesis has been gained from animal models. Homozygous null mice for Klf5 have been generated but die by E8.5 for unexplained reasons (31) . Heterozygous Klf5 mice show abnormalities in cardiovascular remodeling and adipogenesis (22, 31) and reportedly have "misshapen" small intestinal villi, but the description and implication of this finding are unclear.
Recently, ectopic expression of Klf5 in epidermis by the keratin 5 promoter produced embryonic defects in epidermal and craniofacial development (34) . However, the function of Klf5 may be tissue and/or context dependent, and thus the definitive role for Klf5 in epithelial homeostasis Using these mice, we determine that Klf5 is an important regulator of esophageal epithelial cell proliferation but is not sufficient to maintain proliferation in these cells.
Materials and Methods

Generation of ED-L2/Klf5
All animal studies were approved by the Institutional Animal Care and Use Committee (IACUC) at the University of Pennsylvania. To express Klf5 in esophageal epithelia, we excised full length Klf5 cDNA from a cDNA library in pSPORT2 (gift of Dr. Klaus Kaestner, University of Pennsylvania) and cloned this into the pL2 plasmid (gift of Dr. Anil Rustgi, University of Pennsylvania), containing 782 bp of the EBV ED-L2 promoter (17) . The pL2-Klf5 plasmid was sequenced, and the ED-L2/Klf5 fragment was excised for injection. Derivation of transgenic mice was accomplished by the University of Pennsylvania Transgenic and Chimeric Mouse Facility. We documented transgene integration in nine ED-L2/Klf5 founder lines by PCR.
Offspring were screened for transgene expression by RNAse protection assay and immunohistochemistry, as described below. Mice utilized for these experiments were on a mixed genetic background.
Histology
Esophagi were removed from one month-old and one year-old ED-L2/Klf5 mice, examined grossly, and then processed for histology as previously described (15) . Briefly, 
Immunohistochemistry and Quantitation of Cells
We injected control and ED-L2/Klf5 transgenic mice with BrdU Labeling Reagent (Zymed, South San Francisco, California) 90 minutes prior to sacrifice, removed the esophagi, and prepared them as above. Rabbit polyclonal anti-Klf5 and anti-Klf4 were generated (Biosource International/QCB, Hopkinton, MA) as previously described (36) . We performed microwave antigen retrieval and processed the tissues as described (15) , followed by incubation with one of the following primary antibodies: 1:500 sheep anti-BrdU (US Biological, Swampscott, Massachusetts), 1:150 mouse anti-cytokeratin 4 (Lab Vision, Fremont, California), 1:750 rabbit anti-caspase 3 (R&D Systems, Minneapolis, Minnesota), 1:5000 rabbit anti-Klf4 (13), and 1:5000 rabbit anti-Klf5. For co-labeling immunofluorescence, 1:100 goat anti-Klf4 (Santa Cruz Biotechnology, Santa Cruz, California) and 1:5000 rabbit anti-Klf5 were used.
Species-specific secondary antibodies were added and antibody binding detected as described (15) . 
RNA Analyses
RNA was extracted from esophagi or primary esophageal keratinocytes using the RNeasy Mini Kit (Qiagen, Valencia, California) following manufacturer's instructions. Ribonuclease (RNase) protection assays were performed as described previously using 1 µg of total RNA per sample (14) . Probes were designed to span the 3' end of the ED-L2/Klf5 transgene, from the Klf5 cDNA to just upstream of the polyadenylation signal (17) , to protect fragments of 344 bp for endogenous Klf5 and 499 bp for the ED-L2/Klf5 transgene. A 103-nt cyclophilin probe was employed as an internal standard. The RNA fragments obtained were separated on a Novex 6% TBE-urea acrylamide gel (Invitrogen, Carlsbad, California) and the radioactive bands visualized on a Storm 840 phosphorimager (GE Healthcare Bio-Sciences, Piscataway, New Jersey).
Quantitative real-time PCR analysis was performed on a Stratagene Mx4000 Multiplex QPCR System using conditions and primer concentrations suggested by the Brilliant SYBR Green (Stratagene, La Jolla, California) protocol. Reverse transcription was performed with random hexamers and SuperScript II Reverse Transcriptase (Invitrogen, Carlsbad, California). TBP was used as the internal control. Primer sequences are available upon request.
Microarray Analyses
All protocols were conducted as described in the Affymetrix GeneChip Expression Analysis Technical Manual. Briefly, whole esophageal RNA from 3 control and 3 ED-L2/Klf5 transgenic mice at 3 months of age was extracted using the RNeasy Mini Kit (Qiagen) and converted to first-strand cDNA using SuperScript II Reverse Transcriptase (Invitrogen) primed by a poly(T) oligomer that incorporated the T7 promoter. Second-strand cDNA synthesis was and expression values for the probe-set were calculated using GCRMA. Affymetrix "present" or "absent" marginal flags were also calculated. The data were imported into GeneSpring GX version 7.3.1 (Agilent, Santa Clara, California), and filtered based on "present" in at least 2 out of 6 samples. Finally, SAM version 2.2.1 (Stanford University, Stanford, California) was applied using a two-class unpaired analysis, and differentially expressed genes were found using a fold change cutoff of greater than or equal to 2.0 and a false discovery rate of 5%.
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Western Blots
Cells were lysed with 150 mM NaCl, 50 mM Tris pH 7.5, 1% NP 40, 0.5% sodium 
Cell Culture and Analyses
The isolation and culture of mouse primary esophageal keratinocytes has been described elsewhere (1, 37) . Cells were then transduced with pFB-Klf5 retrovirus, containing the fulllength mouse Klf5 cDNA subcloned into the pFB-neo retroviral vector (Stratagene), as described previously (37) , to produce stable overexpression of Klf5, or with the pFB-Klf4 retrovirus, containing the full-length mouse Klf4 cDNA subcloned into pFB-neo, to stably overexpress Klf4.
To overexpress Klf4 and Klf5 simultaneously, primary esophageal keratinocytes stably infected with pFB-Klf5 were transfected at 50% confluence with pMT3-Klf4 (gift of Dr. Vincent Yang) or pMT3 control using FuGENE 6 Transfection Reagent (Roche). Cell growth rates were Page 10 evaluated by MTT assay as described previously (36, 37) . In brief, 1x10 4 cells per well were seeded in triplicate onto 48-well plates in keratinocyte serum-free medium (K-SFM, Invitrogen) supplemented with 40 g/ml bovine pituitary extract (Invitrogen), 1.0 ng/ml epidermal growth factor (EGF) (Invitrogen), 100 U/ml penicillin, and 100 g streptomycin (Invitrogen). At each time-point, medium was removed, and cells were washed with PBS. MTT reagent (USB, Cleveland, Ohio) was added at 2 mg/ml in Hank's buffer (Invitrogen) and incubated for 1 hour until dark blue crystals were seen in the cytoplasm under light microscopy. The crystals were dissolved in DMSO and the absorbance measured at 570 nm with background subtraction at 650 nm in a Beckman DU 600 spectrometer. Results were expressed as the mean of absorbance relative to control ± SEM.
Results
To investigate the role of Klf5 in esophageal epithelial proliferation, differentiation, and tumorigenesis in vivo, we utilized the Epstein Barr Virus ED-L2 promoter to express Klf5 throughout the esophageal epithelium. The ED-L2 promoter has been shown previously to target expression specifically to the tongue, esophagus, and forestomach, all of which are lined by stratified squamous epithelia (1, 17, 23) . We documented transgene integration by PCR in nine Figure   1D ) and 1 year of age ( Figure 1F ). Esophageal epithelial cells normally cease proliferation and undergo differentiation as they migrate through the suprabasal and superficial cell layers (27) .
ED-L2/Klf5 transgenic mice were born at the appropriate Mendelian ratio and survived to at least one year of age. The esophagi and other organs of the ED-L2/Klf5 mice appeared grossly normal. Compared to littermate controls at one month ( Figure 2A ) and one year of age ( Figure   2C ), esophageal epithelia of one month-old ( Figure 2B ) and one year-old ( Figure 2D ) ED-L2/Klf5 transgenic mice appeared normal. All three epithelial cell layers from ED-L2/Klf5 mice were indistinguishable from control, and surface keratinization was preserved. There was no evidence of hypertrophy, hyperplasia, dysplasia, or cancer at any time-point in any of the mice.
Given the evidence implicating Klf5 as a positive regulator of cell proliferation, we hypothesized that Klf5 overexpression in esophageal epithelia would lead to increased proliferation. To investigate cell proliferation, we pulse-labeled cells in S-phase with 5-bromo-2-deoxyuridine (BrdU). Surprisingly, in control mice aged one month ( Figure 3A ) and one year ( Figure 3C ) and ED-L2/Klf5 mice at one month ( Figure 3B ) and one year of age ( Figure 3D Figure 4C ) and ED-L2/Klf5 mice ( Figure 4D ) was unchanged. In addition apoptosis was not significantly altered in ED-L2/Klf5 mice at any age by staining for activated caspase 3, with fewer than one apoptotic cell seen per esophageal cross-section in both control and mutant mice (data not shown).
The KLF family member Klf4 inhibits proliferation and promotes differentiation both in vitro and in vivo (8, 15, (28) (29) (30) . Interestingly, Klf4 and Klf5 have been shown to bind to the same DNA sequence in a number of promoters with opposite effects (6, 9, 26) . When pMT3-Klf4 was introduced into mouse primary esophageal keratinocytes infected with pFB-Klf5, the rate of cell proliferation was significantly decreased by MTT assay, compared to control ( Figure 6A ). In addition, levels of the differentiation marker keratin 13 were increased by Western blot in pFB-Klf5 infected cells with overexpression of Klf4, compared to controls ( Figure 6B ), confirming that Klf4 promotes differentiation of esophageal keratinocytes, even in the presence of Klf5.
To identify additional targets for Klf5 in esophageal epithelia, we performed functional genomic analyses of esophageal tissue from control and ED-L2/Klf5 mice. We identified a total of 18 probe sets covering 15 different genes which were differentially regulated by at least two- (20) , was increased 3.6-fold in ED-L2/Klf5 mice.
Crisp1 (down 12.3-fold in ED-L2/Klf5 mice), which was originally identified in the epididymis where it plays a role in sperm maturation, was recently found to be expressed in murine hair follicles, although its function there has not yet been determined (25) . To confirm the findings on microarray, we performed qPCR on all known genes (excluding Klf5) identified by microarray analyses. Of these 12 genes, we identified 8 genes which had statistically significant changes by qPCR in the same direction as the microarray results (Table 2 ).
Using our primary esophageal epithelial cell culture model, we examined the regulation by Klf4 and Klf5 of two of these genes, Gpsm1, which is downregulated in ED-L2/Klf5 mice compared to controls, and Sorcs2, which is upregulated in ED-L2/Klf5 mice. In primary esophageal keratinocytes, Klf5 reduces Gpsm1 expression while Klf4 upregulates Gpsm1 ( Figure   7a ). In contrast, Sorcs2 expression is increased by Klf5 and decreased by Klf4. To examine How do we reconcile the epidermal hypoplasia seen in mice with Klf5 expression under the control of keratin 5 with our model, in which Klf5 expression resulted in normal appearing epithelia in mice up to one year of age? Several possible explanations exist. First, the effects could be dose dependent. We believe that this explanation is unlikely as Klf5 expression in esophageal epithelia of ED-L2/Klf5 mice was robust (Figure 1) . Alternatively, the consequences of increased Klf5 expression may be tissue dependent and may vary even between the stratified squamous epithelia of the skin and esophagus. To this end, it would be interesting to examine the esophageal epithelia of the K5-Klf5 mice. Finally, K5 but not ED-L2 may target Klf5 to stem
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Page 16 cells, and ectopic Klf5 expression in stem cells may lead to the stem cell depletion, while Klf5 expression in transit amplifying cells of the basal layer leads to increased proliferation.
As described above, we see changes in proliferation in cells of the basal layer in ED-L2/Klf5 transgenic mice, but no gross changes in tissue morphology. This two-fold increase in proliferation could be compensated for by subtle changes in apoptosis and/or cell migration, in order to maintain homeostasis. For example, apoptosis in esophageal basal cells is extremely rare, with fewer than one apoptotic cell seen per esophageal cross-section in both control and mutant mice, making detection of changes extremely difficult. Nonetheless, the changes in proliferation are significant, and, while compensation normally occurs, this balance may be perturbed by tissue injury or malignant transformation.
Using the ED-L2/Klf5 mice, we have identified novel targets for Klf5 in vivo. While some of these have been implicated in proliferation or differentiation in other cell types (20, 25) , the functions of many of these target genes have not been established. Interestingly, the role for Klf5 has been suggested to vary in transformed versus non-transformed cells (2, 36) , and Klf5 has been implicated as a tumor suppressor in a number of cancers, including breast and prostate (3, 4) , suggesting that loss of Klf5 may be critical for tumor progression. Thus, it will be interesting to examine the expression of these target genes during tumorigenesis, and the ED-L2/Klf5 mice will likely form a valuable platform for study of the role of Klf5 in esophageal carcinogenesis in vivo.
The failure of Klf5 to regulate Klf4 expression in vivo contrasts with prior in vitro studies. This disparity may be due to tissue or context dependent effects and highlights the importance of using in vivo models such as the ED-L2/Klf5 mice. One hypothesis consistent with our findings, the results obtained from the K5-Klf5 mice (34) , and the expression patterns of Klf4 and Klf5 in vivo is that Klf5 is critical for the early stages of keratinocyte differentiation, from stem cell to transit amplifying cell, and that Klf4 then takes over to promote further keratinocyte differentiation. In this case, ectopic expression of Klf5 in stem cells would lead to stem cell depletion. Then, in the absence of Klf4 expression, Klf5 would promote and maintain the transit amplifying cell state as described previously (37) . However, in the presence of Klf4, keratinocytes would undergo further differentiation, despite persistent Klf5 expression. We would hypothesize that, in the absence of Klf4, the effects of Klf5 overexpression on epithelial homeostasis would be dramatic, and we are currently testing this hypothesis by crossing the ED-L2/Klf5 mice with mice lacking Klf4 in the esophagus, using Klf4 floxed mice described previously (13) .
In conclusion, we show that Klf5 is a key regulator of esophageal epithelial proliferation in vivo but is not sufficient to maintain proliferation in these cells. We demonstrate that the KLF 
